HDAC inhibitors: double edge sword for TRAIL cancer therapy?
- PMID: 16222120
- DOI: 10.4161/cbt.4.10.2100
HDAC inhibitors: double edge sword for TRAIL cancer therapy?
Comment on
-
Histone deacetylase inhibitors modulate renal cell carcinoma sensitivity to TRAIL/Apo-2L-induced apoptosis by enhancing TRAIL-R2 expression.Cancer Biol Ther. 2005 Oct;4(10):1104-12. doi: 10.4161/cbt.4.10.2022. Epub 2005 Oct 13. Cancer Biol Ther. 2005. PMID: 16096370
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources